SI-Bone Q3 Loss Narrows As Revenue Rises 14.5%; Reaffirms FY26 Revenue Outlook
SI-BONE (SIBN) reported a narrower Q3 loss of $3.62M, with revenue up 14.5% to $55.7M. The company reaffirmed FY26 revenue guidance of $231M-$233M and adjusted EBITDA expectations. U.S. revenue grew 13.9%, driven by procedure volume, while international revenue rose 27%. Cash and investments totaled $146.26M. The stock closed at $20.22, down 4.76%.
How this was made
The 30-second read
Why it matters
The Q3 earnings beat loss expectations and reaffirmed FY26 outlook, providing a modest catalyst for the stock.
Market read
Earnings release with improved loss figures and steady guidance offers limited but actionable insight for traders.
What to watch
Potential impact of new FDA clearance for iFuse Granite Onyx and upcoming Medicare payment changes.
Background
SI‑BONE is a medical‑device company focused on spine and pelvis fusion technologies.
Ticker impact
SI-BONE reported Q3 loss narrowing to $3.62M and reaffirmed FY26 revenue guidance, a fresh earnings disclosure.
potential slight upward pressure as the market prices in the improved loss and unchanged guidance
First report of earnings with better loss figures; no surprise guidance change, so impact is limited.
Market effects
Positive for the spine‑fusion device sector as volume growth continues.
Limited to U.S. healthcare investors; no broader regional effect.
Low; the news is company‑specific.
Counterpoint
The reaffirmed guidance may already be priced in, limiting upside despite the loss improvement.
Key entities
- companySI‑BONE, Inc.
Medical‑device maker reporting Q3 results.
